Toll-Like Receptor 4 Activation in Cancer Progression and Therapy

Abstract EN

Cancer immunotherapy has been the focus of intense research since the late 19th century when Coley observed that bacterial components can contribute to cancer regression by eliciting an antitumor immune response.

Successful activation and maturation of tumor-specific immune cells is now known to be mediated by bacterial endotoxin, which activates Toll-like receptor 4 (TLR4).

TLR4 is expressed on a variety of immune as well as tumor cells, but its activation can have opposing effects.

While TLR4 activation can promote antitumor immunity, it can also result in increased tumor growth and immunosuppression.

Nevertheless, TLR4 engagement by endotoxin as well as by endogenous ligands represents notable contribution to the outcome of different cancer treatments, such as radiation or chemotherapy.

Further research of the role and mechanisms of TLR4 activation in cancer may provide novel antitumor vaccine adjuvants as well as TLR4 inhibitors that could prevent inflammation-induced carcinogenesis.